Global Cancer Technology
GCT’s lead cancer technology is its remote-controlled cancer drug delivery platform.
Overview
Raised: $24,400
Rolling Commitments ($USD)
09/29/2021
$67
14
2017
Healthcare & Pharmaceuticals
HealthTech
San Diego, California
Balance Sheet
Cash and Cash Equivalents |
$70,706 |
Property, Plant and Equipment (PP&E) |
$175 |
Total Assets |
$320,881 |
Accounts Payable & Accrued Liabilities |
$153,923 |
Total Liabilities |
$383,035 |
Total Stockholders' Equity |
$-62,154 |
Total Liabilities and Equity |
$320,881 |
Statement of Comprehensive Income Information
Depreciation and Amortization |
$174 |
Net Income |
$-140,421 |
Earnings Per Share - Basic |
$0.01 |
Earnings Per Share - Diluted |
$0.01 |
Raise History
Offering Name | Close Date | Platform | Valuation/Cap | Total Raised | Security Type | Status | Reg Type |
---|---|---|---|---|---|---|---|
Global Cancer Technology | 04/28/2022 | Netcapital | $26,682,636 | $0 | Equity - Common | Not Funded | RegCF |
Global Cancer Technology | 09/07/2021 | Dalmore Group | - | $24,400 | Equity - Common | Funded | RegA+ |
Global Cancer Technology | 02/24/2020 | Netcapital | $11,571,400 | $107,000 | Equity - Common | Funded | RegCF |
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.
Valuation History
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Employee History
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual